Monocytic resilience during chemoradiotherapy is independently associated with survival in IDH-Wildtype glioblastoma.
Immune cell resilience during brain cancer treatment independently predicts survival beyond standard clinical measures.
This diagnostic validation study examined Monocytic resilience during chemoradiotherapy is independently associated with survival in IDH-Wildtype glioblastoma. The abstract reports that This dynamic signal remained associated with survival after adjustment for established clinical factors, baseline monocyte burden, lymphocyte change, systemic inflammatory imbalance, and measured corticosteroid exposure.
What the study was
- Study design
- Diagnostic validation study
- Population
- Human participants
- Sample size
- 102
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- J Neurooncol
Why it surfaced
Diagnostic validation study; directly matches Aging, longevity, and population health. Conservative abstract-level score 8/10.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.